Table 1.
Clinical and pathological characteristics of 34 female patients with inflammatory breast carcinomas evaluated in this study.
| Features | Number of Patients (%) 2 |
|---|---|
| Age (years) | |
| <50 | 10 (29) |
| ≥50 | 24 (71) |
| Family history of cancer | |
| No | 9 (26) |
| Yes | 23 (68) |
| Breast and/or ovarian cancer | 12 (35) |
| Unknown | 2 (6) |
| Body Mass Index (Kg/m2) | |
| ≤24.9 (Normal) | 7 (20) |
| 25 to 30 (Overweight) | 5 (15) |
| >30 (Obese) | 20 (59) |
| Unknown | 2 (6) |
| Histological grade 1 | |
| I | 1 (3) |
| II | 14 (41) |
| III | 19 (56) |
| Clinical stage | |
| III | 21 (62) |
| IV | 13 (38) |
| Hormone receptor (ER or PR) /HER2 status | |
| +/+ | 0 |
| +/− | 18 (53) |
| −/+ | 5 (15) |
| TNBC | 11 (32) |
| Distant metastases | |
| No | 8 (24) |
| Yes | 26 (76) |
| At diagnosis (Stage IV) | 13 (38) |
| During follow-up | 13 (38) |
| Survival status | |
| Alive | 7 (20) |
| Dead | 25 (74) |
| Loss of follow-up | 2 (6) |
+, positive; –, negative; ER, estrogen receptor; PR, progesterone receptor; TNBC, triple-negative breast cancer. 1 according to Scarf Bloom Richardson grading system. 2 DNA was obtained from 24 of 34 patients. Microarray and tNGS were performed in 24 and 21 patients, respectively. Eighteen cases were submitted to immunohistochemistry analysis, eight of them were also evaluated by microarray and targeted next-generation sequencing (except one). Ten cases were used exclusively in the IHC experiments.